In all, 26 out of 70 (37.1%) patients had triple-negative breast cancer (TNBC), 23 out of 70 (32.9%) were oestrogen receptor (ER)-positive/HER2-negative and 21 out of 70 (30.0%) were HER2-positive. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.